Rates of Protein Synthesis Are Reduced in Peripheral Blood Mononuclear Cells (PBMCs) from Fragile X Individuals

Olivier Dionne (✉ olivier.dionne@usherbrooke.ca)

Universite de Sherbrooke Faculte de medecine et des sciences de la sante <https://orcid.org/0000-0002-0531-9761>

Audrey Lortie

Universite de Sherbrooke Faculte de medecine et des sciences de la sante

Florence Gagnon

Universite de Sherbrooke Faculte de medecine et des sciences de la sante

François Corbin

Universite de Sherbrooke Faculte de medecine et des sciences de la sante

---

Research

Keywords: Fragile X Syndrome, Protein synthesis, Biomarker, PBMCs, Radiolabelling, Blood Platelets

Posted Date: October 7th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-85010/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability and is caused by the loss of expression of the Fragile X mental retardation protein (FMRP). In animal model of FXS, the absence of FMRP leads to an aberrant rate of neuronal protein synthesis, which in turn is believed to be at the origin of defects regarding spine morphology and synaptic plasticity. Normalisation of protein synthesis in these models has been associated with a rescue of FXS behavioral and biochemical phenotype, thus establishing the rate of protein synthesis as one of the most promising monitoring biomarker for FXS. However, rate of protein synthesis alteration in fragile X individuals is not well characterized

Method

We applied a robust radiolabeled assay to measure rate of protein synthesis in freshly extracted peripheral blood mononuclear cells (PBMCs) and blood platelets. We ultimately settle on PBMCs to measure and compare rate of protein synthesis in 13 males with fragile X and 14 matched controls individuals.

Results

Using this method, we measured a 26.9% decrease ($p = 0,0193$) in the rate of protein synthesis in fragile X individuals PBMCs. Furthermore, the rate of protein synthesis measurements obtained were highly reproducible, highlighting the robustness of the method.

Conclusion

Our work presents the first evidence of a diminution of the rate of protein synthesis in a human peripheral model of fragile X. Our results also support the finding of previous studies using brain PET imaging in Fragile X individuals. Since our assay only requires a simple venous puncture, it could be used in other cases of intellectual disability in order to determine if an aberrant rate of protein synthesis is a common general mechanism leading to impairment in synaptic plasticity and to intellectual disability.

Background

Fragile X syndrome (FXS) is the most common monogenic cause of intellectual disabilities (ID) and autism spectrum disorders. Aside from cognitive dysfunctions, fragile X (FX) individuals are prone to develop a wide range of medical and behavioral problems [1, 2]. The vast majority (> 99%) of FX cases arise from the runaway expansion of CGG repeats found in the 5' UTR of the *FMR1* gene and by the subsequent methylation of CpG islands in its promoter. This phenomenon ultimately results in the transcriptional silencing of *FMR1* and subsequent loss of expression of the Fragile X mental retardation protein (FMRP) [3–5]. FMRP is well-conserved across species and expressed in nearly every cells or tissues, including lymphocytes and platelets [6, 7]. FMRP is a RNA-binding protein mainly associated with

polyribosomes [8] that would mainly acts as a translational regulator of its targeted mRNAs. Previous studies have reported that FMRP binds approximately 4% of brain mRNA, a subset likely to be essential for the regulation of synaptic plasticity and spine morphogenesis [9, 10]. Consequently, the absence of FMRP, and its concomitant effect on translational regulation, would cause the cognitive and behavioral impairments found in FXS

The generation of the *Fmr1* KO mouse allowed the investigation of the impact of FMRP absence on brain's protein synthesis. Utilizing this model, in conjunction with different *in vitro*, *ex vivo* and *in vivo* experimental techniques, several groups have reported a FMRP-dependant increase in the global rate of protein synthesis [11–14]. Moreover, its normalisation using targeted drugs has been associated with the rescue of the FX phenotype; bringing dysregulation of the rate of protein synthesis as a cornerstone of FX physiopathology and as a potential objective outcome measure for FXS clinical trials [15–20]. However, this global increase in protein synthesis do not completely reflects the impact of FMRP's absence on mRNA translation, as some proteins are also found downregulated or not affected in such context [21]. Furthermore, it's still unclear if the net increase in protein synthesis found in KO mice brains is present in every developmental stage, tissue or even in FX individuals.

Characterizing brain's rate of protein synthesis non-invasively in human is not an easy task. As such, only two studies have addressed this issue in FXS individuals using positron emission tomography (PET) imaging. The first report concluded that the rate of protein synthesis is lower in FXS brains subjected to propofol sedation (Qin et al., 2013). Although not statistically significant, the same group recently reported a similar effect using dexmedetomidine as a sedating agent instead of propofol; thereby strongly suggesting that the observed decreased in the rate of protein synthesis is not caused by sedating agents [23]. These reports shed new light on translational regulation in FXS and highlights limitations of the *Fmr1* KO mouse model to fully replicate FXS phenotype and the necessity to further study FX subjects in order to get a better understanding of the human physiopathology [24]. Such task represents a substantial challenge due to the inaccessibility and invasive nature of neuronal tissue, thus emphasizing the need to use a less invasive model.

We and others have previously shown that peripheral blood cells are great surrogate model for studying mechanisms underlying FXS physiopathology and clinical response. Indeed, both PBMCs (peripheral blood mononuclear cells) [25–28] and platelets [29–32] have shown to reproduce some of the core biochemical phenotypes of FX neurons. Furthermore, blood cells collection is minimally invasive and can be achieved repeatedly, making them ideal for clinical trials [31]. However, rate of protein synthesis in these cells has not been well studied.

The goal of this study was to determine, using freshly isolated peripheral blood cells (PBMCs and platelets), if the rate of protein synthesis is either increased or decreased in FXS patients as compared to matched controls. In order to increase our chance to observe a statistical difference in the rate of protein synthesis between FX individuals and healthy controls, only fully mutated FX males were recruited. Our results obtained in PBMCs, showing a decrease rate of protein synthesis, support the findings of the

previously mentioned PET imaging studies and acknowledge PBMCs as a brain's accessible surrogate model.

Methods

Study population and ethics

We performed a transversal study including one group of 13 FX and a group of 14 healthy controls, all males matched for age. Participants were recruited through the Fragile X Clinic, at the *CIUSSS de l'Estrie-CHUS* (Sherbrooke, Québec, Canada). Informed written consent was obtained directly from healthy controls or through a caregiver for FXS participants in accordance with requirements of the Ethics Review Board of the *CIUSSS de l'Estrie-CHUS*. All participants had a blood draw in the morning. FXS individuals had cognitive evaluations as well, performed by a certified neuropsychologist.

PBMCs isolation

Blood samples were collected by venipuncture into ACD tubes (acid citric dextrose, BD Vacutainer®). All subsequent steps were performed at room temperature. PBMCs were subsequently extracted by density gradient using Ficoll-Paque (Ge Healthcare®) following the manufacturer protocol with minor modifications. Briefly, blood samples were centrifuged at 300 g for 10 minutes to allow separation and collection of plasma rich platelets (PRP). A volume of PBS, equal to the volume of plasma collected, was then added to each tube. The blood samples were carefully placed onto a layer of Ficoll-Paque (blood:Ficoll-Paque ratio of 4:3) and centrifuged at 500 g for 30 minutes. PBMCs were thereafter isolated from the interface and collected by centrifugation (500 g, 10 minutes). Cell pellets were washed twice with PBS and counted on a DXH-9000 hematology analyzer (Beckman Coulter®).

Platelets isolation

Platelets were extracted from blood sample collected in 8 mL ACD tubes as previously described [30]. Briefly, PRP was separated from whole blood by centrifugation (300 g, 10 minutes). Afterwards, platelets were sedimented from the PRP (2400 g, 15 minutes) and washed twice with PBS containing 5 mM EDTA and counted on a DXH-9000 hematology analyzer (Beckman Coulter®).

Rate of proteins synthesis rate assay

Protein synthesis rate assay is schematised in Fig. 1. Freshly extracted PBMCs were suspended into RPMI 1640 Met⁻/Cys⁻ (supplemented with 2 mM L-Glutamine, Sigma) and incubated for 30 minutes at 37 °C under 5% CO₂ with gentle agitation. Following methionine and cysteine depletion, PBMCs were diluted to 2 million cells/mL and 0,5 mL of this culture were incubated with 50 µCi/mL of [³⁵S] radiolabeled methionine and cysteine (Perkin Elmer®) at 37 °C (5% CO₂) under gentle agitation for either 20, 40 or 60 minutes. The latter procedure was performed in triplicate. PBMCs were then pelleted by centrifugation (500 g, 10 minutes) and lysed in PBS containing 2% SDS. Proteins were precipitated overnight at 4 °C in 20% trichloroacetic acid and pelleted by centrifugation (14 000 g, 15 minutes). After

two washes with acetone, proteins were suspended in 0.1N NaOH and their radiolabelled content was measured by liquid scintillation. Protein synthesis rate was normalised according to cell count and expressed in cpm/min/ 10^6 PBMCs. Radiolabeled amino acids incorporation was limited to 60 minutes to ensure unbiased normalisation by cell count (See Additional file 1). Experimental conditions including the number of cells, the timeframe and the concentration of radiolabeled amino acids used were rigorously optimised to ensure that the incorporation was linear and provides enough signal strength.

The same assay was used to measure protein synthesis rate in quiescent blood platelets with some minor modifications. After methionine and cysteine depletion, platelets were diluted to 200 million cells/mL and incubated with 250 μ Ci/mL of [^{35} S] radiolabeled methionine and cysteine. Platelets were then incubated under gentle agitation at 37 °C under 5% CO₂ for periods of 30, 60 and 120 minutes (triplicates) and subsequently collected by centrifugation (2400 g, 15 minutes). The same protocol as described for PBMCs was used for protein precipitation and liquid scintillation counting. Protein synthesis rate was also normalised to the concentration of cells and expressed in CPM/min/ 100^6 platelets.

Cognitive evaluation

FXS participants had a cognitive evaluation including three different scales validated for the French-Canadian population. First, the Wechsler Adult Intelligence Scale third edition (WAIS-III) was used to evaluate intelligence quotient. Second, the Aberrant Behavior Checklist-Community Edition refactored for FXS (ABC-C_{FX}) and the Adaptive Behavior Assessment System (ABAS-II) were administered to assesses aberrant and adaptive behavior respectively. Third, the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) was used to evaluate the executive functions

Statistical analysis

All results are expressed as means $\pm$ standard error of the mean (SEM). The non-parametric Mann-Whitney test was used to compare differences in protein synthesis rate between the two groups. Protein synthesis rate correlation with clinical parameters were accessed by both Pearson and Spearman correlation. All statistical tests were two-tailed, and a $p < 0.05$ was considered significant. All statistical analysis was conducted in GraphPad Prism (8.4.0).

Results And Discussion

Population characteristics

The study population include two male groups: 13 FX subjects with a mean age of $28,4 \pm 4,6$ years and 14 healthy controls, with a mean age of $30,8 \pm 7,8$ years. Individual characteristics of each participant, including age, FX diagnostic and medication are listed in Additional file 2.

Platelets ^{35} S incorporation rate is too low for efficient protein synthesis measurement

The methodology used in this study was based on radiolabelled amino acids incorporation method to ensure an unbiased and robust measurement of proteins synthesis [33]. Using this method, we first investigated the relevance of using blood platelets for the monitoring of protein synthesis rate alterations in FXS. Indeed, platelets are one of the most valuable peripheral model for FX due to their close biochemical similarities with neuron and the fact that they replicate some of FXS core molecular alterations [31]. However, the translational machinery of platelets is scarce and devoted to the production of a limited number of proteins during its short lifespan of 10 to 14 days [35]. As expected, even after optimization of the method, the rate of protein synthesis is barely measurable in platelets (Fig. 2A-B) making them unsuitable for our purpose.

We therefore decided to use PBMCs, which also replicate some of FX core biochemical and molecular defects, as a model to monitor protein metabolism alteration in FXS. Following adjustment for protein content of cells, protein synthesis rate measured in PBMCs is 3 thousand-fold higher than in platelets (Fig. 2A-B). This observation clearly demonstrates that PBMC's rate of protein synthesis is sufficiently high to assess differences between FXS and control population.

Rate of protein synthesis is decrease in fragile X PBMCs

One of the greatest challenge encounters when undergoing *ex vivo* experiments on human peripheral cells is the individual heterogeneity inherent to the use of such models. The sources of this interindividual variability are highly diverse (genetic background, epigenetic factor, life habits, drugs consumption, etc.) and can easily concealed differences between control and affected cells. A stringent and robust experimental protocol is thus mandatory to limit those fluctuations and ensure results reliability. In concordance with this mindset, we firstly ascertain our assay optimization by investigating intraindividual variability. As illustrated in Fig. 3A, our method shows an intraindividual variability inferior to 10%, even when measurements were made several months apart (Table 1). This great reproducibility will obviously facilitate our ability to detect small difference regarding rate of protein synthesis between FX and CTL PBMCs. Therefore, we confidently measured rates of protein synthesis from PBMCs obtained from 13 FX males and 14 matched control individuals. The average rate of protein synthesis was 1830 ± 141 cpm/min for the FX group as compared to 2500 ± 194 cpm/min for the control group (Fig. 3B). This represent a 26.9% decrease of PBMCs rate of protein synthesis in the FX cohort ($p = 0.0193$). No correlation was found between subject age and rate of protein synthesis in both groups (Additional file 3).

Table 1: Rate of protein synthesis measurement reproductibility

(Should be place with or after Figure 3)

ID	Mean rate of protein synthesis measurement (cpm/min)	Absolute Difference between replicate	Variation (Difference/Mean)	Days elapsed between replicate
Fragile X patients				
X1	2209	62	2.8%	175
X4	1438	326	22.7%	35
X8	1646	137	8.3%	70
X10	1734	69	4.0%	63
X13	1453	99	6.8%	29
Control individuals				
C1	2469	66	2.7%	4 and 107
C2	2221	40	1.8%	214
C3	2632	194	7.4%	131
C4	3270	125	3.8%	126
C5	1356	268	19.7%	164
C6	2897	26	0.9%	125
C7	2111	374	17.7%	155
C10	1684	231	13.7%	9

To our knowledge, our results constitute the very first report of a decreased in the rate of protein synthesis in a human peripheral cellular model of FX. As such, the decreased protein synthesis rate measured in FX PBMCs is in concordance with the only two reports to ever addressed that topic in FX neurons. Indeed, the Beebe Smith group used PET imaging to measure a decreased in [^{11}C] leucine integration into nascent brain proteins of FX individuals in two independent studies. This fact, in addition to the great reproducibility shown by our method, clearly demonstrates the relevance of using PBMCs as a model to investigate translational alterations in FXS.

Our observations are different to those reported in actively dividing cells, namely FX fibroblasts, where an increase in protein synthesis was observed. The translational machinery in such cells is much more active and focused on sustaining the resource-intensive processes of cellular division whereas in non-proliferative cells, protein synthesis is limited and mainly dedicated to cell maintenance. It is therefore conceivable that the absence of FMRP may have opposite effect in cells having contrasting translational processes. In this regard, we believe that the alterations in the rate of protein synthesis found in FX

PBMCs may display with more fidelity the defect found in neurons, which are also terminally differentiated cells. The adverse trend in protein synthesis defects between PBMCs and fibroblasts may also be explained by divergence regarding FMRP function between those two models.

Curiously, the two fibroblasts-based studies report poor reproducibility of the measurements made exclusively in FXS cell lines. Human skin fibroblasts gradually loose their potency to divide during cell passages and protein synthesis rate is affected along the way. The reported large differences in protein synthesis rate in FX fibroblasts replicates could be the signature of distinct effect of FMRP in protein synthesis whether the potency to divide of the cells is still high or at time they get into senescence. Alternatively, the culture conditions used in those two studies may have also influence the translational activity by inducing a metabolic stress on the fibroblasts, a phenomenon that can impact rate of protein synthesis measurement in a FMRP-dependant manner [36].

For those reasons, we believe that the use of a freshly extracted and non-proliferative model will give a better reflection of the protein metabolism found in neuron, which are primary and terminally differentiated cells, than immortalised or long-lasting cultured cellular models.

Assessment of PBMCs rate of protein synthesis as a biomarker for FXS

In order to ascertain the pathophysiological role of protein synthesis in FXS, we evaluated the association between rate of protein synthesis and the clinical phenotype of FX individuals Unfortunately, such correlations were not observed for the cognitive evaluations assessed in this study (Fig. 4, Table 2 and additional file 4). Similar results were obtain with a larger cohort of fibroblasts derived from 21 FX males [37].

Table 2: Association between rate of protein synthesis measurements and cognitive evaluations

(Should be place after or with Figure 4)

Variable	Pearson correlation		Spearman correlation	
	r	p	r	p
ABC-C score	-0.195	0.616	-0.250	0.521
Full Scale IQ	0.239	0.569	0.156	0.716
Brief score	0.234	0.545	0.251	0.511
ABAS II score	-0.250	0.517	-0.293	0.442

This lack of association in our study can easily be explained by the study design. Indeed, we purposely recruited fully mutated FX males in order to restrain the heterogeneity of the FX cohort enrolled.; the downside being that all FX subjects presents low cognitive profile. Our strategy, combined with a highly

reproducible methodology, allowed us to monitor a significant difference between the FX and control group with a relatively small sample size. On the other hand, this approach did not allow us to get a comprehensive portrait of the translational defect in a sample representative of the entire FX population. As such, our data cannot rule out if the amplitude of the rate of protein synthesis alteration found in FX individuals is related to the severity of the clinical presentation; such observations being out of the scope of the present study.

Clinical trials of FXS are currently limited by the lack of objective tools to assess treatment efficiency in individuals. The development of such monitoring biomarkers could drastically improve the scope of those studies and promotes a better understanding of the human physiopathology [38]. As seen in animal researches, rate of protein synthesis normalisation could be used to address this issue [18, 19]. We truly believe that the method described in this paper is well suited for this task. Indeed, our radiolabeled assay showed great intraindividual reproducibility and robustness, which mean that it could easily detect improvement in rate of protein synthesis upon treatment. Furthermore, unlike fibroblasts, PBMCs are a well designated model for human trials due to their non-invasive nature, ease of collection and the fact that they replicated the protein synthesis defect found in FX neurons [22, 23]. Nonetheless, the utilisation of this procedure in large multi-center trial might be somewhat limited due to the fact that it must be done in a timely fashion.

Conclusion

Our work presents the first evidence of a diminution of protein synthesis rate in a human peripheral model of FX, supporting the results obtained from FX brains by PET imaging [22, 35]. These observations highlight the limitations of animal models to fully replicates the complete spectrum of FX phenotypes and that rate of protein synthesis alterations are still a misunderstood hallmark of FXS. This highlight the need of studying human models and subjects to better understand the impact of FMRP's absence on translation and its contribution to FX physiopathology.

Abbreviations

ACD
Acid citric dextrose
Cys
Cysteine
FMR1
Fragile X mental retardation 1 gene
FMRP
Fragile X mental retardation protein
FX
Fragile X
FXS

Fragile X syndrome
ID
Intellectual disability
Met
Methionine
NaOH
Sodium hydroxide
PBS
Phosphate buffer saline
PBMCs
Peripheral blood mononuclear cells
PET
Positron emission tomography
PRP
Platelets rich plasma
RPMI
Roswell Park Memorial Institute medium
SDS
Sodium dodecyl sulfate

Declarations

Acknowledgements

We warmly thank all participants and their family for their participation in this study. We are grateful to Pr. Édouard Khandjian, Dr. Artuela Çaku, and Pr. Luc Galarneau for critical review of the manuscript.

Ethics approval and consent to participate

This study was conducted according to the World Medical Association Declaration of Helsinki. Informed written consent was obtained directly from healthy controls or through a caregiver for FXS participants in accordance with requirements of the Ethics Review Board of the *CIUSSS de l'Estrie-CHUS*.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this article. If any additional information is required, it may be obtained by request from the corresponding author.

Competing interest

The authors declare that they have no competing interest.

Funding

This work was supported by the Centre de Recherche du CHUS and the Foundation of the Stars. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. OD holds a Frederick Banting and Charles Best Canada Graduate Scholarship Master Award from the Canadian Institutes of Health Research (CIHR) and a Master Scholarship from the Fonds de Recherche du Québec – Santé (FRQS). A.L. holds a Master scholarship from Fondation du Grand défi Pierre Lavoie.

Authors contribution

FC and OD designed the study. FC requested funding, supervised the study, recruited fragile X individuals and revised the manuscript. AL, FG and OD carried out assay optimisation. OD performed further experiments, data analysis, wrote the first draft and recruited control individuals. All authors read and approved the final manuscript.

References

1. Ciaccio C, Fontana L, Milani D, Tabano S, Miozzo M, Esposito S. Fragile X syndrome: a review of clinical and molecular diagnoses. *Ital J Pediatr* [Internet]. 2017 [cited 2019 Nov 19];43. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395755/>
2. Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, McBrien D, et al. Fragile X Syndrome: A Review of Associated Medical Problems. *Pediatrics*. 2014;134:995–1005.
3. Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang W-Y, Gerhardt J, et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. *Science*. 2014;343:1002–5.
4. Pieretti M, Zhang F, Fu Y-H, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. *Cell*. 1991;66:817–22.
5. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell*. 1991;65:905–14.
6. Khandjian EW. Biology of the fragile X mental retardation protein, an RNA-binding protein. 1999;77:14.
7. Lauzière V, Lessard M, Meunier AJ, McCoy M, Bergeron LJ, Corbin F. Unusual subcellular confinement of the fragile X mental retardation protein (FMRP) in circulating human platelets: Complete polyribosome dissociation. *Biochimie*. 2012;94:1069–73.
8. Corbin F, Bouillon Marlène, Fortin Anny, Morin S, Rousseau F, Khandjian EW. The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. *Human*

- Molecular Genetics. 1997;6:1465–72.
9. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. *Cell*. 2001;107:477–87.
  10. Darnell JC, Van Driesche SJ, Zhang C, Hung KYS, Mele A, Fraser CE, et al. FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism. *Cell*. 2011;146:247–61.
  11. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. *J Neurosci*. 2005;25:5087–95.
  12. Bowling H, Bhattacharya A, Zhang G, Alam D, Lebowitz JZ, Bohm-Levine N, et al. Altered steady state and activity-dependent de novo protein expression in fragile X syndrome. *Nat Commun* [Internet]. 2019 [cited 2019 Jul 16];10. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461708/>
  13. Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome. *Journal of Neuroscience*. 2010;30:15616–27.
  14. Gross C, Nakamoto M, Yao X, Chan C-B, Yim SY, Ye K, et al. Excess Phosphoinositide 3-Kinase Subunit Synthesis and Activity as a Novel Therapeutic Target in Fragile X Syndrome. *Journal of Neuroscience*. 2010;30:10624–38.
  15. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, et al. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice. *Neuron*. 2012;74:49–56.
  16. Gross C, Raj N, Molinaro G, Allen AG, Whyte AJ, Gibson JR, et al. Selective Role of the Catalytic PI3K Subunit p110 β in Impaired Higher Order Cognition in Fragile X Syndrome. *Cell Reports*. 2015;11:681–8.
  17. Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, et al. Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen. *Science Translational Medicine*. American Association for the Advancement of Science; 2012;4:152ra128-152ra128.
  18. Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. *Nature Medicine*. 2017;23:674–7.
  19. Osterweil EK, Chuang S-C, Chubykin AA, Sidorov M, Bianchi R, Wong RKS, et al. Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome. *Neuron*. 2013;77:243–50.
  20. Dölen G, Osterweil E, Rao BSS, Smith GB, Auerbach BD, Chattarji S, et al. Correction of Fragile X Syndrome in Mice. *Neuron*. 2007;56:955–62.
  21. Bechara EG, Didiot MC, Melko M, Davidovic L, Bensaid M, Martin P, et al. A Novel Function for Fragile X Mental Retardation Protein in Translational Activation. Wickens M, editor. *PLoS Biology*. 2009;7:e1000016.

22. Qin M, Schmidt KC, Zametkin AJ, Bishu S, Horowitz LM, Burlin TV, et al. Altered Cerebral Protein Synthesis in Fragile X Syndrome: Studies in Human Subjects and Knockout Mice. *Journal of Cerebral Blood Flow & Metabolism*. 2013;33:499–507.
23. Schmidt KC, Loutaev I, Quezado Z, Sheeler C, Smith CB. Regional rates of brain protein synthesis are unaltered in dexmedetomidine sedated young men with fragile X syndrome: A L-[1-11C]leucine PET study. *Neurobiology of Disease*. 2020;143:104978.
24. Dahlhaus R. Of Men and Mice: Modeling the Fragile X Syndrome. *Front Mol Neurosci*. 2018;11:41.
25. Berry-Kravis E, Hicar M, Ciurlionis R. Reduced Cyclic AMP Production in Fragile X Syndrome: Cytogenetic and Molecular Correlations. *Pediatr Res*. 1995;38:638–43.
26. Hoeffler CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H, et al. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with Fragile X syndrome. *Genes Brain Behav*. 2012;11:332–41.
27. Schutzius G, Bleckmann D, Kapps-Fouthier S, di Giorgio F, Gerhartz B, Weiss A. A quantitative homogeneous assay for fragile X mental retardation 1 protein. *Journal of Neurodevelopmental Disorders*. 2013;5:8.
28. Weng N, Weiler IJ, Sumis A, Berry-Kravis E, Greenough WT. Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 2008;147B:1253–7.
29. Berry-Kravis E, Sklena P. Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. *American Journal of Medical Genetics*. 1993;45:81–7.
30. Lessard M, Chouiali A, Drouin R, Sébire G, Corbin F. Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome. *Clinical Genetics*. 2012;82:472–7.
31. Pellerin D, Lortie A, Corbin F. Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome. *Platelets*. 2018;29:113–24.
32. Pellerin D, Çaku A, Fradet M, Bouvier P, Dubé J, Corbin F. Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet's signaling cascades as new outcome measures in clinical trials. *Biomarkers*. 2016;21:497–508.
33. Hidalgo San Jose L, Signer RAJ. Cell-type-specific quantification of protein synthesis in vivo. *Nature Protocols*. Nature Publishing Group; 2019;14:441–60.
34. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Protein Synthesis by Platelets: Historical and New Perspectives. *J Thromb Haemost*. 2009;7:241–6.
35. Schubert P, Devine DV. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. *Vox Sanguinis*. 2010;99:112–22.
36. Pal R, Bhattacharya A. Modelling Protein Synthesis as A Biomarker in Fragile X Syndrome Patient-Derived Cells. *Brain Sci* [Internet]. 2019 [cited 2019 Oct 3];9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468675/>

37. Jacquemont S, Pacini L, Jønhc AE, Cencelli G, Rozenberg I, He Y, et al. Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. Hum Mol Genet. 2018;27:2039–51.

38. Westmark CJ. The quest for fragile X biomarkers. Molecular and Cellular Pediatrics. 2014;1:1.

Figures

Figure 1

Schematic representation of the rate of protein synthesis assay

Figure 1

Schematic representation of the rate of protein synthesis assay

Figure 2

Comparison between rate of protein synthesis measured in PBMCs and platelets: (A) Rate of protein synthesis were compared between PBMCs and platelets of 4 control individuals. Rate of protein synthesis measurement in PBMCs is greater (3 order of magnitude) than in platelets. (B) Typical result obtained from a control PBMCs and platelets. All results were normalised according to protein quantification to ensure correct comparison between both cell types.

Figure 2

Comparison between rate of protein synthesis measured in PBMCs and platelets: (A) Rate of protein synthesis were compared between PBMCs and platelets of 4 control individuals. Rate of protein synthesis measurement in PBMCs is greater (3 order of magnitude) than in platelets. (B) Typical result obtained from a control PBMCs and platelets. All results were normalised according to protein quantification to ensure correct comparison between both cell types.

Figure 3

A decreased rate of protein synthesis is observed in fragile X PBMCs: (A) Reproducibility of the protein synthesis rate measurement. Each dot indicates a single experiment. (B) PBMCs rates of protein synthesis measurement obtained from 14 controls males and 13 FX males. A 26.9% decrease is observed (mean $\pm$ SEM) in the FX group (1830 ± 150 CPM/min) when compare to the control group (2500 ± 194 CPM/min). Error bars represent the SEM. Mann Whitney test.

Figure 3

A decreased rate of protein synthesis is observed in fragile X PBMCs: (A) Reproducibility of the protein synthesis rate measurement. Each dot indicates a single experiment. (B) PBMCs rates of protein synthesis measurement obtained from 14 controls males and 13 FX males. A 26.9% decrease is observed (mean $\pm$ SEM) in the FX group (1830 ± 150 CPM/min) when compare to the control group (2500 ± 194 CPM/min). Error bars represent the SEM. Mann Whitney test.

Figure 4

No association between rate of protein synthesis in fragile X individuals PBMCs and cognitive evaluation: (A) ABC-C score (B) Full Scale IQ (C) Brief score and (D) ABAS-II score. No clear correlation is observed.

Figure 4

No association between rate of protein synthesis in fragile X individuals PBMCs and cognitive evaluation: (A) ABC-C score (B) Full Scale IQ (C) Brief score and (D) ABAS-II score. No clear correlation is observed.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Add.file4Dionneetal.2020J.Neurodev.Disorders.xlsx](#)
- [Add.file4Dionneetal.2020J.Neurodev.Disorders.xlsx](#)
- [Add.file3Dionneetal.2020J.Neurodev.Disorders.pptx](#)
- [Add.file3Dionneetal.2020J.Neurodev.Disorders.pptx](#)
- [Addfile2Dionneetal.2020J.Neurodev.Disorders.xlsx](#)
- [Addfile2Dionneetal.2020J.Neurodev.Disorders.xlsx](#)
- [Add.file1Dionneetal.2020J.Neurodev.Disorders.pptx](#)

- [Add.file1Dionneetal.2020J.Neurodev.Disorders.pptx](#)